IDH1N2 - Is JAC Inhibition Controlling Myal Aprylifaration?

The number of patients is relatively low because if the quarter of our malhebrasus patients progress and quarter of them have IDH mutations. But it really works very well, but it's not forever like in any other acute myal leukemia setting. And you see IDH1N2? Yes. And do you see differentiation syndrome? Well, from my experience, now we have probably up to 20 patients in one or two cases,. Perhaps JAC inhibition is controlling that myal aprylifaration. Really interesting.